Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2007-04-30 | Stephen J. Sullivan, age 60. Mr. Sullivan became a director in September 2004. ... The Audit Committee is currently composed of Mr. Stover (chairperson), Mr. Sullivan and Dr. Curti. ... The Nominating Committee is currently comprised of Messrs. Pietruski (chairperson), Federspiel and Sullivan and Dr. Curti. ... Stephen Sullivan Fees earned or paid in cash ($) 42,083, Stock awards ($) 8,751, Option awards ($) 21,840, Total ($) 72,674. |
| 2008-04-28 | Stephen J. Sullivan, age 61. Mr. Sullivan became a director in September 2004. ... The Audit Committee is currently comprised of Mr. Stover (chairperson), Mr. Sullivan and Dr. Curti. ... The following table presents information relating to total compensation for our non-employee directors for the year ended December 31, 2007. ... Stephen Sullivan 40,000 fees + 23,750 stock awards + 9,100 option awards = 72,850 total. |
| 2009-04-24 | Stephen J. Sullivan, age 62. Mr. Sullivan became a director in September 2004. ... The Audit Committee is currently comprised of Mr. Stover (chairperson), Mr. Belle, Ms. Lubatkin and Mr. Sullivan. ... The Nominating Committee is currently comprised of Messrs. Federspiel (chairperson) and Sullivan and Dr. Curti. ... Stephen Sullivan 40,000 Fees earned or paid in cash ($) 41,247 Stock awards ($) 81,247 Total ($) |
| 2010-04-30 | Stephen J. Sullivan, age 63. Mr. Sullivan became a director in September 2004. ... The Audit Committee is currently comprised of Mr. Stover (chairperson), Mr. Belle, Ms. Lubatkin and Mr. Sullivan. ... The Nominating Committee is currently comprised of Messrs. Federspiel (chairperson), Belle and Sullivan. ... Stephen Sullivan (2) $40,000 $45,002 - - - 85,002 |
| 2011-04-28 | Stephen J. Sullivan, age 64. Mr. Sullivan became a director in September 2004. ... The Audit Committee is currently comprised of Mr. Stover (chairperson), Mr. Belle, Ms. Lubatkin and Mr. Sullivan. ... The Nominating Committee is currently comprised of Messrs. Federspiel (chairperson), Belle and Sullivan. ... Stephen Sullivan (2) 40,000 45,000 - - - 85,000 |
| 2012-04-27 | Stephen J. Sullivan became a director in September 2004. ... The Audit Committee is currently comprised of Mr. Stover (chairperson), Mr. Belle, Ms. Lubatkin and Mr. Sullivan. ... The Nominating Committee is currently comprised of Messrs. Federspiel (chairperson), Belle and Sullivan. ... Director Compensation ... Stephen Sullivan ... Total ($) ... 99,502. |
| 2013-04-30 | Stephen Sullivan is a director since September 2004, Chairperson of the Compensation Committee, and member of the Nominating Committee. His fees represent the annual director's fee of $40,000, an additional $8,571 for Chair of the Compensation Committee, plus $5,000 for serving on multiple committees, and $12,000 for participation in the 2012 Special Advisory Committee, totaling $110,578. |
| 2014-04-28 | Stephen J. Sullivan who has been a director since September 2004, is Chairman of the Compensation and Management Development Committee of the Company (the “Compensation Committee"). ... Mr. Sullivan has held senior leadership positions in companies in the life sciences and healthcare services industries. ... The Compensation Committee is currently comprised of Messrs. Sullivan (chairperson), Federspiel, Mr. Climaco and Ms. Lubatkin. ... Mr. Sullivan’s fees represent the annual director’s fee of $40,000, plus an additional $15,000 fee paid to Mr. Sullivan for his service as Chair of the Compensation Committee, plus a fee of $5,000 for serving on multiple committees. Mr. Sullivan also received $12,000 for his participation in the 2013 Special Advisory Committee. |
| 2015-04-30 | Stephen J. Sullivan joined us as a director in September 2004, and is the Chairman of our Compensation & Management Development Committee (the “Compensation Committee”). ... Mr. Sullivan’s fees represent the annual director’s fee of $40,000, plus an additional $15,000 fee paid to Mr. Sullivan for his service as Chair of the Compensation Committee. Mr. Sullivan also received $12,000 for his participation in the 2014 Special Advisory Committee, plus a fee of $5,000 for serving on multiple committees. |
| 2016-06-22 | Mr. Sullivan was appointed Chairman of the Board effective June 21, 2016. Mr. Sullivan joined us as a director in September 2004 and has served as Chairman of various committees of the Board. Mr. Sullivan's fees represent the annual director's fee of $40,000, plus an additional $15,000 fee paid to Mr. Sullivan for his service as Chair of the Compensation Committee, and a fee of $5,000 for serving on multiple committees. Total compensation $105,000. |
| 2017-08-14 | Stephen J. Sullivan was appointed Chairman of the Board effective June 21, 2016. Mr. Sullivan currently serves as Chairman of the Company27s Compensation and Management Development Committee. Mr. Sullivan27s fees represent the annual director27s fee then in effect of $40,000, plus the $30,000 Chairman of the Board fee, and a fee of $5,000 for serving on multiple committees. |
| 2018-04-30 | Mr. Sullivan’s fees represent the annual director’s fee of $30,000, plus the $20,000 Chairman of the Board fee, plus the $10,000 Chair of the Compensation Committee fee, and a fee of $5,000 for serving on multiple committees. |
| 2019-08-22 | Stephen J. Sullivan was appointed Chairman of the Board effective June 21, 2016. Mr. Sullivan currently serves as Chairman of the Compensation & Management Development Committee (the “Compensation Committee”). The following table presents information relating to total compensation for our non-employee directors for the year ended December 31, 2018. Stephen J. Sullivan: Fees earned ($) 65,000, Stock awards ($) 4,848, Option awards ($) 17,280, Total ($) 87,128. |
| 2019-11-14 | Stephen J. Sullivan Currently serves as Chairman of the Board. |
| 2020-06-10 | Stephen J. Sullivan is currently a director and served as Chairman of the Board from June 21, 2016 until April 16, 2020. Mr. Sullivan served as Interim Chairman of the Board from January 1, 2016 to June 20, 2016. Mr. Sullivan joined Interpace as a director in September 2004 and has served as Chairman of various committees of the Board. Mr. Sullivan currently serves as Chairman of the Compensation Committee and a member of the Audit and Nominating Committees. Mr. Sullivan’s fees represent the annual director’s fee of $30,000, plus the $20,000 Chairman of the Board fee, plus the $10,000 Chair of the Compensation Committee fee, and a $5,000 fee for serving on multiple committees. |
| 2021-09-27 | Stephen J. Sullivan is currently a director and served as Chairman of the Board from June 21, 2016 until April 16, 2020. Mr. Sullivan currently serves as Chairman of the Compensation Committee and a member of the Audit and Nominating Committees. Director Compensation in 2020 Stephen J. Sullivan Fees earned or paid in cash: $53,750 Stock awards: $0 Option awards: $136,186 All other compensation: $0 Total: $189,936. |
| 2022-09-20 | Stephen J. Sullivan is currently a director and served as Chairman of the Board from June 21, 2016 until April 16, 2020... Mr. Sullivan currently serves as Chairman of the Compensation Committee and a member of the Audit and Nominating Committees... Mr. Sullivan received $50,000 in fees earned or paid in cash in 2021. |
| 2023-09-22 | Stephen J. Sullivan is currently a director and served as Chairman of the Board from June 21, 2016 until April 16, 2020. Mr. Sullivan served as Interim Chairman of the Board from January 1, 2016 to June 20, 2016. Mr. Sullivan joined Interpace as a director in September 2004 and has served as Chairman of various committees of the Board. Mr. Sullivan currently serves as Chairman of the Compensation Committee and a member of the Audit and Nominating Committees. In early 2010, Mr. Sullivan founded CRO Advisors LLC, a specialty consulting firm he continues to head. Previously, Mr. Sullivan was the president and chief executive officer and a member of the board of directors of Harlan Laboratories, Inc. ("Harlan") (acquired by Huntingdon Life Sciences Inc.), a privately held global provider of preclinical research tools and services, from February 2006 through January 2010, when he retired from that position. Prior to joining Harlan in 2006, Mr. Sullivan was a senior vice president of Covance, Inc. ("Covance") and the president of Covance Central Laboratories, Inc., a major division of Covance. Prior to joining Covance, Mr. Sullivan was chairman and chief executive officer of Xenometrix, Inc. ("Xenometrix"), a biotechnology company with proprietary gene expression technology. He assisted with the merger of Xenometrix with Discovery Partners International. Prior to Xenometrix, Mr. Sullivan was vice president and general manager of a global diagnostic sector of Abbott Laboratories. Mr. Sullivan has extensive experience as a director. In 2019, Mr. Sullivan became a director of The Emmes Company, LLC, a clinical research collaborator within the contract research organization industry. In July of 2022, The Emmes Company LLC was sold to New Mountain Capital, at which time Mr. Sullivan resigned from the board. Since April 2018, Mr. Sullivan has been a member of the board of Transnetyx, Inc., a privately held genotyping company. Since May 2015, Mr. Sullivan has been chairman of the board of Analytical Lab Group (formerly known as Microbiology Research Associates), a privately held microbiology services company. In May of 2020, Analytical Lab group was sold to Element, a UK company, at which time Mr. Sullivan resigned as Chairman and left the board. From April 2011 through March 2019, Mr. Sullivan was chairman of the board of MI Bioresearch, Inc. (formerly known as Molecular Imaging, Inc.), a privately held venture-backed drug discovery services company. In February of 2020, MI Bioresearch was sold to LabCorp, at which time Mr. Sullivan resigned as Chairman and left the board. In January 2016, Mr. Sullivan became chairman of the board of H2O Clinical (acquired by Pharma Start LLC). In July 2016, Mr. Sullivan became chairman of the board of PharmaStart, LLC. As of June 2017, both H20 Clinical and PharmaStart are doing business as Firma Clinical Research, a privately held specialty contract research organization. As of July 2018, Firma Clinical Research has been sold and Mr. Sullivan is no longer a member of its board. From November 2015 until August 2017, Mr. Sullivan was a member of the board of Accel Clinical Research, a phase 1 contract research organization. From June 2013 through January 2016, when the company was sold, Mr. Sullivan was the chairman of the board of BioreclamationIVT, LLC, a privately-owned bio-materials company. From May 2013 through March 2015, when the company was sold, Mr. Sullivan was a member of the board of directors of PHT Corporation (acquired by eResearchTechnology, Inc.), a privately-owned leader in electronic patient recorded outcomes in clinical trials. Mr. Sullivan graduated from the University of Dayton, was a commissioned officer in the Marine Corps, and completed his M.B.A. in Marketing and Finance at Rutgers University. Mr. Sullivan is currently an adjunct Professor of Management at Georgetown University. Mr. Sullivan has held senior leadership positions in companies in the life sciences and healthcare services industries. His specific qualifications and skills in the areas of general operations, financial operations and administration, and mergers and acquisitions led the Board to conclude that Mr. Sullivan should serve as a director of the Company. |
| 2024-09-20 | Stephen J. Sullivan is currently a director and served as Chairman of the Board of the Company from June 21, 2016 until April 16, 2020... Mr. Sullivan currently serves as Chairman of the Compensation Committee and a member of the Audit and Nominating Committees... The following table presents information relating to total compensation for our non-employee directors for the year ended December 31, 2023... Stephen J. Sullivan 62,500 - 62,500 |
Data sourced from SEC filings. Last updated: 2026-03-05